Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy

HIV Medicine

Volumn 9, Issue 9, 2008, Pages 765-770

  Charpentier, Charlotte ^a,b   Karmochkine, M ^a   Laureillard, D ^a   Tisserand, P ^a   Belec L ^a,b   Weiss, L ^a,b   Si mohamed, A ^a   Piketty, C ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

HIV; Integrase; Raltegravir; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

ARTICLE; CELL CLONE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE ISOLATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR CLONING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SALVAGE THERAPY; SEQUENCE ANALYSIS; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; PARIS; PYRROLIDINONES; SALVAGE THERAPY; SEQUENCE ANALYSIS, RNA; TREATMENT FAILURE; VIRAL LOAD;

EID: 54049102468     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00628.x     Document Type: Article

References (18)

1. Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 2006; 20: 489-501.
2. Cooper D, Gatell J, Rockstroh J et al. for the BENCHMRK-1 Study Group. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, February 2007 [Abstract 105aLB].
3. Steigbigel R, Kumar P, Eron J et al. for the BENCHMRK-2 Study Group. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, February 2007 [Abstract 105bLB].
4. Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369: 1261-1269.
5. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125-133.
6. Fikkert V, Van Maele B, Vercammen J et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77: 11459-11470.
7. Hazuda DJ, Anthony NJ, Gomez RP et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA 2004; 101: 11233-11238.
8. Jones G, Ledford R, Yu F et al. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, February 2007 [Abstract 627].
9. Hazuda DJ, Miller MD, Nguyen BY, Zhao J. Resistance to the HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection. XVI International HIV Drug Resistance Workshop. Barbados, West Indies, June 2007 [Abstract 8].
10. McColl DJ, Fransen S, Gupta S et al. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase 2 study of elvitegravir (GS-9137). XVI International HIV Drug Resistance Workshop. Barbados, West Indies, June 2007 [Abstract 9].
11. Malet I, Delelis O, Valantin MA et al. Biochemical characterizations and drug sensitivity of the effect of mutations selected in HIV-1 integrase gene associated with failure to raltegravir (MK-0518). XVI International HIV Drug Resistance Workshop. Barbados, West Indies, June 2007 [Abstract 7].
12. Herring BL, Cunningham AL, Dwyer DE. Potential drug resistance polymorphisms in the integrase gene of HIV type 1 subtype A. AIDS Res Hum Retroviruses 2004; 20: 1010-1014.
13. Vingerhoets J, Buelens A, Peeters M et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the Phase III clinical trials DUET-1 and DUET-2. XVI International HIV Drug Resistance Workshop. Barbados, West Indies, June 2007 [Abstract 32].
14. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12: 563-570.
15. Yerly S, Hirschel B, Gaille C et al. Polymorphism of HIV-1 subtypes B and non-B integrase genes. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, February 2007 [Abstract 626].
16. Thompson JD, Higgins DG, Gibson TJ. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
17. Kishino H, Hasegawa M. Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data, and the branching order in hominoidea. J Mol Evol 1989; 29: 170-179.
18. Page RD. TreeView: An application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996; 12: 357-358.